Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic therapy comparison of HAL, BF-200 ALA, and MAL for superficial basal cell carcinoma
2014-002746-50Phase 4Completed
- Sponsor
- Mari Salmivuori
- Start
- Jul 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of hexaminolevulinate, 5-aminolevulinic acid and methyl aminolevulinate in basal cell carcinoma (BCC) (3 arms), sponsored by Mari Salmivuori. Primary endpoint: Histological cure of basal cell carcinomas. Started Jul 2014; status: completed.
02
Drugs
hexaminolevulinate5-aminolevulinic acidmethyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2014-002746-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002746-50.